This was the second year in which I presented an all-day seminar on our approach to neurofeedback. The audience grew this year to fill the room, and many others apparently picked up the handout. I presented a lot of theory, but most were waiting for the goods on how we actually do things, which I saved until the end and covered only cursorily. Sue and I are somewhat ambivalent about putting the material out there in this fashion, since the use of the inter-hemispheric protocol is a two-edged sword. The one-day seminar is supposed to be the “appetizer” for the clinical course, but most will probably just take the material I presented and run with it.
My other major pre-occupation at the conference was our Symposium on Migraine. This was preceded the day before by another such symposium, where the emphasis was on conventional biofeedback therapies and pharmacology for migraine. Deb Stokes was attending the AAPB Conference for the first time and was shocked that this conference would be a vehicle for such a preoccupation with drug treatment. The title of the Symposium was “New Frontiers in Migraine Headache,” and appeared to offer nothing new at all. That symposium was led by the incoming president of the AAPB, Steve Baskin. I have talked with him over the years about our migraine work, and never was able to make an impression. Over most of that time, he was of course still tethered to the vascular model of migraines. Over the last few years he has also been drawn into pharmacological studies, and when you get paid $3000 per patient for a drug study, it’s hard to make room for biofeedback. One could even say that his professional well-being is more dependent on drug company success than biofeedback success. Continue reading “Report on the 35th AAPB Meeting, Colorado Springs, CO”